10.1002/hbm.20708 Hum
Read more: Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study reuters.com GLP-1/GIP agonists in HFpEF: real-world outcomes (JAMA 2025) 5 US cohort studies, 20182024 Primary endpoint: HF hospitalization or all-cause mortality (52 wks) Semaglutide (n=58,333) vs sitagliptin HR 0.58 (95% CI 0.510.65) Absolute risk 3.2% NNT ~31 Tirzepatide (n=11,257) vs sitagliptin HR 0.42 (95% CI 0.310.57) Absolute risk 3.9% NNT ~26 Head-to-head (n=28,100): Tirzepatide vs semaglutide HR 0.86 (95% CI 0.701.06) Risk difference 0.1% NNT ~1000 (no meaningful difference) Benchmarked against STEP-HFpEF DM & SUMMIT results consistent
If its something that the healthcare vendors that youre working with provide, educate above and beyond what they provide, she said
Fiber management also matters significantly
No Calorie Counting The standard calories in versus calories out idea has oversimplified what it means to fuel and nourish our bodies, boiling our health down to a set of numbers rather than the complex, brilliant ecosystem that it is
Both theories are serious, but they require different experts, different medical proof, and different trial stories
